Pharmacotherapy for obsessive-compulsive disorder

E. Hollander, A. Kaplan, A. Allen, C. Cartwright

Research output: Contribution to journalArticlepeer-review

27 Scopus citations

Abstract

SSRIs and the tricyclic antidepressant clomipramine are the first-line therapies for patients with OCD, with the side-effect profile of SSRIs being more favorable than that of clomipramine. As many as 40% to 60% of patients with OCD may not respond to adequate trials of SRIs. Not all patients tolerate SSRIs, and delays in full therapeutic responses often occur. Thus, other pharmacologic approaches to treating patients with OCD have been investigated. Augmentation and monotherapy have been explored with serotonergic enhancers, dopamine and 5-HT antagonists, enhancers of second-messenger systems, and GABAergic agents with varying efficacy.

Original languageEnglish (US)
Pages (from-to)643-656
Number of pages14
JournalPsychiatric Clinics of North America
Volume23
Issue number3
DOIs
StatePublished - Jan 1 2000
Externally publishedYes

ASJC Scopus subject areas

  • Psychiatry and Mental health

Fingerprint Dive into the research topics of 'Pharmacotherapy for obsessive-compulsive disorder'. Together they form a unique fingerprint.

Cite this